Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study
Background: Elexacaftor/Tezacaftor/Ivacaftor (ETI) for people with CF (PwCF) after lung transplantation (LTx) has been restrained due to uncertainties regarding efficacy and drug interactions. Given the persistence of extrapulmonary symptoms post-LTx, this prospective study aims to investigate the b...
Saved in:
Main Authors: | Johanna P. van Gemert, Bart Luijk, Merel E. Hellemons, Klara A. Visser, Carina.M.E. Hansen, Renske van der Meer, C. Tji Gan, Hester van der Vaart, Onno W. Akkerman, Willie N. Steenhuis, Marieke Verkleij, Harry G.M. Heijerman, Erik A.M. Verschuuren |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | JHLT Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2950133425000059 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
by: Tahuanty A. Pena, MD, MS, et al.
Published: (2025-02-01) -
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
by: Angela Pepe, et al.
Published: (2025-02-01) -
Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders
by: Fancheng Liu, et al.
Published: (2025-02-01) -
Godsdiens en Samelewing. Christelike betrokkenheid op die markplein
by: BJ van der Walt
Published: (2000-06-01) -
On the trail of John Calvin's philosophy of language: a few notes on his commentary on Genesis 10 and 11
by: N. T. van der Merwe
Published: (2004-01-01)